Ellipses Pharma featured in Nature Research Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D. Read the full article here. 

EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]

Expansion of Scientific Affairs Group More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses [...]

Ellipses Pharma features in SCRIP Ellipses Pharma has been featured in SCRIP. Read the full article here.

Ellipses Pharma announces FDA approval of IND application for EP0042 for patients with acute myeloid leukaemia IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042’s ongoing phase 1/2 trial Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and [...]